SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Oscient Pharmaceuticals Corp. (OSCI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Tara Cobble who wrote (60)9/8/1996 11:31:00 AM
From: Jeff Lee   of 1154
 
Hi Tara. I know your message was for John but since I've owned some shares of ARRS since
May of 1995 I thought I could relay some info to you. At this level ARRS sure looks
like a buy. Arris research and initial product development programs are focused in two
major areas: protease inhibitor-based therapeutics for multiple therapeutic applications;
and oral cytokine and growth factor mimetics. Now when the stock popped above $19 there was alot
of positive talk about pro-tease inhibitors in treating aids. The big news event that will
move this stock and should happen anytime is the decision whether Bayer will pick up development
of their promising asthma drug APC366. If Bayer picks up development costs profitability could be
accelerated by 1-2 years. Profitability with out Bayer should be year 2000. Cowen has a strong but
with a price target of $18-20. H & Q has a buy with a target of $20. Paine Webber buy with a target
of $21. Good luck....regards

Jeff
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News